SWOG clinical trial number
CTSU/A151216

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Open
Phase
Abbreviated Title
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Activated
08/18/2014
Participants
CTSU

Research committees

Lung Cancer

Eligibility Criteria Expand/Collapse

SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute. Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org) for more information and registration procedures.

Publication Information Expand/Collapse

2021

Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients in The U.S. ALCHEMIST Study (Alliance)

K Kehl;D Zahrieh;P Yang;S Hillman;A Tan;J Sands;G Oxnard;E Gillespie;D Wigle;S Malik;T Stinchcombe;S Ramalingam;K Kelly;S Mandrekar;R Osarogiagbon;D Kozono WCLC World Conference on Lung Cancer (September 8-14, 2021, virtual), mini-oral, #MA15.05

2018

Adjuvant targeted therapy following standard adjuvant therapy for resected NSCLC: An initial report from ALCHEMIST (A151216)

J Oxnard;S Mandrekar;S Hillman;A Tan;R Govindan;S Malik;C Watt;D Gerber;J Chaft;S Dahlberg;D Gandara;K Kelly;S Ramalingam;T Stinchcombe IASCL (WCLC) (September 23-26, 2018, Toronto, CAN), abst.#P1.16-47, IASLC Book of Abstracts p. 421

Other Clinical Trials

SWOG Clinical Trial Number
S2302

PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Research Committee(s)
Lung Cancer
Activated
03/06/2023
Accrual
76%
Open
Phase
SWOG Clinical Trial Number
A082002

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007

RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open